Cirdan secures £4m Salica Investments deal to drive global expansion of pathology platform

Northern Ireland digital health firm Cirdan has agreed a £4 million venture debt facility with London-based Salica Investments, marking the investment firm's first deployment of capital in Northern Ireland and providing fresh impetus for the Lisburn company's international growth ambitions.

According to the Irish News, the deal forms part of a broader £12.9 million funding package announced last month and will support the continued development and global rollout of Vision Path, Cirdan's next-generation pathology informatics platform. Alongside the Salica facility, Cirdan has secured over £3 million in additional equity investment, including £1.25 million from 57 Stars.

Cirdan's technologies are currently used in laboratories and hospitals across multiple international markets, with operations spanning the UK, Australia and Canada. The company said its platforms help healthcare professionals deliver faster and more accurate diagnoses while improving efficiency across healthcare systems, processing millions of laboratory tests per month.

Chief executive Hugh Cormican said the partnership with Salica strengthens the company's capacity to scale. "Their support, alongside the continued backing of our investors, strengthens our ability to accelerate growth and expand into new international markets. Vision Path represents the next generation of pathology informatics, bringing together data, imaging and AI to modernise diagnostic workflows and support faster, more accurate diagnoses for patients around the world."

Stephen Fahy, venture debt partner at Salica Investments, said the firm was impressed by Cirdan's growth trajectory. "We have been hugely impressed with their growth journey and innovation to date and look forward to supporting their exciting growth plans, as Cirdan continue to develop advanced diagnostic technologies and embed deep tech functionality in its imaging and LIS products."

Read the full story on Cirdan's funding round and expansion strategy